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Abstract The Fas/Fas ligand interaction plays a crucial role in
various liver diseases, and administration of agonistic anti-Fas
antibody to mice causes massive hepatic apoptosis and fulminant
hepatic failure. Several growth factors have recently been found
to function in preventing apoptosis. In this study, we demon-
strated that overexpression of transforming growth factor K
(TGFK) has a dramatic protective effect on Fas-mediated hepatic
apoptosis at the biochemical and histological levels. Moreover,
85.7% (six out of seven) of TGFK transgenic mice survived the
lethal liver damage, whereas all wild-type mice died. Expression
of Bcl-xL, an anti-apoptotic protein, was greatly increased in the
transgenic mice. Taken together, our findings suggest that TGFK
protects against Fas-mediated liver apoptosis in vivo and up-
regulation of Bcl-xL may participate in protective effect of
TGFK. , 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis, programmed cell death, is the most common
form of eukaryocytic cell death [1] and plays an important
role during embryonic development and in adult tissues. Dis-
ruption of apoptosis, however, can contribute to illegitimate
cell survival and cause tumors to develop [2].
Fas/APO-1/CD95 is a 45 kDa glycoprotein and a member
of the tumor necrosis factor (TNF)/nerve growth factor
(NGF) receptor family [3]. Fas ligand, which is predominantly
expressed in activated T cells, binds to Fas and can transmit
the signals for cell death to target cells, resulting in the in-
duction of apoptosis [3,4]. It is now clear that the Fas/Fas
ligand interaction is related to a number of diseases, including
viral hepatitis, alcoholic liver disease, and hepatocellular car-
cinoma [5^13]. Constitutive expression of Fas has been ob-
served in normal mouse and human hepatocytes [14], and
treatment with agonistic Fas antibody results in massive liver
apoptosis and fulminant liver failure in mice [15^17].
Transforming growth factor alpha (TGFK) is structurally
and functionally related to members of the epidermal growth
factor (EGF) family that bind to EGF receptor [18], and it is
a potent mitogen for epithelial cells in many organs. TGFK
promotes wound healing [19] and plays a pivotal role in liver
regeneration after partial hepatectomy [20,21]. Numerous hu-
man solid tumors, including hepatocellular carcinoma, express
high levels of TGFK [22^25], and we previously reported that
TGFK transgenic mice developed liver neoplasia [26,27].
Some growth factors, such as hepatocyte growth factor
(HGF) and NGF, have been found to be capable of protect-
ing cell against apoptosis [28^30]. Recent studies have shown
that TGFK and EGF also relate to suppress apoptosis in-
duced by various stimuli in vitro [31^35]. The mechanism of
this e¡ect in vivo, however, remains poorly understood. To
clarify the relationship between TGFK and apoptosis in vivo,
TGFK transgenic mice were used to analyze the protective
e¡ect of TGFK against liver apoptosis, particularly Fas-medi-
ated apoptosis in this study.
2. Materials and methods
2.1. Mice
Transgenic mouse line MT100 bearing the metallothionein^TGFK
fusion gene was created as described previously [36]. MT100 mice
have expressed human TGFK transgene under the control of mouse
metallothionein 1 promoter on a FVB mouse background. In this
study we used 6- to 8-week-old male MT100 mice (TG) and non-
transgenic littermates (WT). All animal studies were performed ac-
cording to the guidelines for animal care and use established by Gun-
ma University School of Medicine.
2.2. Experimental protocol and histological examination
Mice were injected intraperitoneally with 0.15 mg/kg of a mouse
monoclonal agonistic Fas antibody (Jo2, PharMingen, CA, USA). At
speci¢ed time points, mice were sacri¢ced and their serum and organs
were collected. Serum alanine aminotransferase (ALT) levels were
measured at each time point, and liver samples were ¢xed in 10%
formalin, embedded in para⁄n and stained with hematoxylin and
eosin. For hepatic caspase 3-like activity assay, 0.3 mg/kg of agonistic
Fas antibody was administered intraperitoneally and mice were sacri-
¢ced 5 h later. To assess survival times, mice were injected intraperit-
oneally with 0.3 mg/kg of Jo2 antibody and observed for survival up
to 72 h.
2.3. In situ analysis of liver apoptosis by terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate biotin nick end
labeling (TUNEL) assay
TUNEL assay was performed to detect apoptotic cells. Brie£y,
para⁄n-embedded sections were dewaxed in xylene and rehydrated
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by passage through a graded series of ethanol solutions, ending with
PBS. Sections were permeabilized with proteinase K. After washing,
the 3P-OH ends of DNA fragments were stained by the method de-
scribed by the manufacturer (In situ Apoptosis Detection kit; Apop-
Tag Direct, Oncor, Gaithersburg, Germany). Sections were viewed
and photographed by standard £uorescence microscopy techniques.
TUNEL positive cells per U200 high power ¢eld were counted.
2.4. Hepatic caspase 3-like protease activity assay
Liver tissues were homogenized and the lysate was centrifuged at
15 000 rpm for 15 min. Supernatant proteins were incubated at 37‡C
with caspase 3 substrates, Ac-DEVD-pNA (Medical and Biological
Laboratories, Nagoya, Japan) and the liberated p-NA was measured
at 405 nm. Non-speci¢c reaction was corrected by subtracting the
background readings from the combination of the lysates and bu¡ers.
2.5. Western blotting analysis
Total liver protein from the mice was homogenized in RIPA bu¡er
containing phenylmethylsulfonyl £uoride, pepstatin, leupeptin, and
aprotinin (Roche Diagnostics GmbH, Mannheim, Germany). The
supernatants were used for Western blotting analysis. Total protein
(20 Wg) was separated on a SDS^PAGE gel, transferred to polyvinyl-
idene di£uoride membranes, and blocked in 5% skim milk in Tris-
bu¡ered saline containing 0.1% Tween 20 before incubation with anti-
body (anti-mouse Bcl-xL antibody; a kind gift from Dr. Y. Tsujimo-
to, Osaka University, anti-mouse L-actin and Bax; Santa Cruz Bio-
technology, CA, USA, anti-mouse Bcl-2 and Bad; BD Transduction
Laboratories, NJ, USA). Enhanced chemiluminescense (Amersham
Pharmacia, UK) was used to detect apoptosis.
2.6. Statistical analysis
Statistical analysis was performed by two-way analysis of variance
for serum ALT levels and hepatic caspase 3-like protease activity, by
unpaired t-test for the number of TUNEL positive cells. All values are
expressed as meansRS.E.M. Survival rate was assessed by the Kap-
lan^Meier method, and di¡erences in curves were tested by the log
rank test. P6 0.05 was accepted as statistically signi¢cant.
3. Results
3.1. Changes in serum ALT levels following anti-Fas antibody
injection
As shown in Fig. 1, the mean serum ALT levels of the WT
mice at 0, 12 and 24 h were 50R 3, 11 292R 3286, 2446R 1554
IU/l, respectively, and those of the TG mice were much lower:
48R 9, 1647R 1308 and 550R 342 IU/l, respectively
(P=0.0178). It was particularly striking that the serum ALT
levels of TG mice at 12 h were suppressed to approximately
one-seventh their level of the WT mice.
3.2. Histopathological examination after anti-Fas antibody
injection
Histological examination revealed that injection with anti-
Fas antibody induced more massive hepatocyte apoptosis
Fig. 1. Serum ALT levels following anti-Fas antibody injection. The
TG mice had signi¢cantly lower serum ALT levels after Fas-medi-
ated liver injury than the WT mice (n=5 per group). P=0.0178.
Fig. 2. Histological ¢ndings in the liver 12 h after anti-Fas antibody injection. A: Liver from WT mouse. B: Liver from TG mouse. Arrows
point to typical apoptosis of hepatocytes: acidophilic bodies. The liver apoptosis was much less severe in the TG mouse than in the WT mouse.
(HE staining; original magni¢cation U200)
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around the portal area in the WT mice (Fig. 2A) than in the
TG mice (Fig. 2B). Numerous acidophilic bodies resulting
from Fas-mediated hepatocyte apoptosis were observed in
the WT mice. The livers of the WT mice (Fig. 3A) and the
TG mice (Fig. 3B) mice were analyzed by TUNEL staining to
further assess the induction of apoptosis in the liver following
anti-Fas injection. More than 70 TUNEL positive cells/high
power ¢eld on average were found in WT mice. In contrast,
only 10 TUNEL positive cells/high power ¢eld were found in
TG mice. TG mice suppressed Fas-mediated liver apoptosis in
compared with WT mice (Fig. 3C; P6 0.001).
3.3. Hepatic caspase 3-like protease activity after anti-Fas
antibody injection
Caspase 3-like protease activity was assessed by cleavage of
the peptide substrate Ac-DEVD-pNA in the liver homoge-
nates. As shown in Fig. 4, this activity was almost equal
between WT and TG mice before injection and there was a
four-fold increase in WT mice 5 h after injection. However,
this activity in TG mice 5 h after injection was signi¢cantly
decreased relative to WT mice at same time (P=0.0043).
3.4. Cumulative survival after Fas-induced lethal liver injury
Severe liver failure occurred rapidly after injection of a
lethal dose (0.3 mg/kg) of anti-Fas antibody injection, and
all of the WT mice were dead within 28 h. By contrast, six
out of seven TG mice (85.7%) survived the lethal challenge
(Fig. 5), showing that the lethal liver failure following anti-
Fas antibody injection was signi¢cantly inhibited in the TG
mice compared to the WT mice (P=0.0029).
3.5. Changes in anti-apoptotic and pro-apoptotic proteins in
mouse liver
To assess the expression of the Bcl-2 family apoptosis-re-
lated protein, Western blotting analysis was performed for
Bcl-2, Bcl-xL, Bax, and Bad (Fig. 6). Two of the members
of the Bcl-2 family, Bcl-2 and Bcl-xL proteins, act as anti-
apoptotic agents, while Bax and Bad act as pro-apoptotic
agents. The expression of the pro-apoptotic proteins, Bax
and Bad, remained unchanged in the TG mice, and Bcl-2
protein expression was too weak to detect in either the WT
or TG mice. Expression of the anti-apoptotic protein Bcl-xL,
however, was markedly higher in the TG mice both before
injection (TG 0 h) and 12 h after injection (TG 12 h).
Fig. 3. TUNEL staining of a WT and TG mouse after injection of
anti-Fas antibody. Section of WT (A) and TG (B) mouse liver tak-
en 12 h after injection. Many TUNEL positive cells were detected
in the WT mouse, but a few TUNEL positive cells were seen in the
TG mouse (original magni¢cation U200). TUNEL positive cells per
U200 high power ¢eld were counted (C). TUNEL positive cells
were signi¢cantly decreased in TG mice. P6 0.001.
Fig. 4. Hepatic caspase 3-like protease activity after injection of
anti-Fas antibody. Caspase 3-like protease activities were measured
0 and 5 h after injection of 0.3 mg/kg anti-Fas antibody (n=4 per
group). All values were normalized to WT mice at 0 h (set at 1.0).
There was a four-fold increase of caspase 3-like protease activity in
the liver of WT mice 5 h after injection. In contrast, this activity in
the TG mice 5 h after injection was signi¢cantly suppressed.
P=0.0043
Fig. 5. Survival rate of TG and WT mice after administration of
anti-Fas antibody, 0.3 mg/kg body weight. The TG mice show a
drastically improved survival rate (n=7 per group). P=0.0029.
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4. Discussion
We demonstrated a protective e¡ect of TGFK on liver ap-
optosis induced by the Fas pathway in vivo. Consistent with
the results of vitro studies [31^34], TGFK protects against
c-myc and TNFK-induced apoptosis in some cell types,
although it was ¢rst identi¢ed as a potent mitogen resembling
EGF [24]. EGF protects epithelial cells [35] and primary cul-
tured hepatocytes [37] from Fas-induced apoptosis in vitro. Its
protective e¡ects were concentration-dependent [32] and
greater overexpression of TGFK might completely suppress
apoptosis in vivo.
It has recently been concluded that a variety of key events
in apoptosis converge on mitochondria and that the release of
cytochrome c from mitochondria triggers cell apoptosis [38].
The anti-apoptotic Bcl-2 family protein Bcl-xL is located on
the outer mitochondrial membrane and inhibits the release of
cytochrome c, resulting in maintenance of cell survival [39^
41]. Boise et al. reported observing that Bcl-xL inhibits apo-
ptosis in Jurkat T cells treated with Fas antibodies and main-
tains cell viability by preventing the loss of mitochondrial
membrane potential [42]. We found that TGFK transgenic
mice constitutively express more Bcl-xL protein than wild-
type mice. Analysis of the Bcl-xL transgenic mice revealed
that Bcl-xL could inhibit both Fas- and TNFK-induced hepa-
tocyte apoptosis [43]. Accordingly, up-regulation of Bcl-xL
may partially take part in suppressing liver apoptosis driven
by Fas antibody injection.
Bcl-2 can also prevent liver apoptosis [44,45], but expression
of Bcl-2 was so much lower than that of other Bcl-2 family
proteins that it could not be detected on Western blots. The
pattern of Bcl-2 expression in the transgenic mice was similar
to that in WT mice. Bax and Bad, on the other hand, can
promote cell death to regulate the release of cytochrome c
[41,46], and Rb protein overexpression has been documented
to down-regulate Bax protein and protect against Fas-medi-
ated liver apoptosis in mice [47]. In our study, Bcl-2, Bax, and
Bad expression were relatively constant, compared with Bcl-
xL, in both the wild-type mice and the transgenic mice. Since
the balance between anti-apoptotic and pro-apoptotic Bcl-2
family proteins is important for the regulation of apoptosis,
the increased expression of Bcl-xL but similar expression of
other Bcl-2 family proteins can cooperate to protection
against liver apoptosis.
EGF receptor signaling controls the expression of Bcl-xL in
keratinocytes [48,49], mammary epithelial cells [31], squamous
cell carcinoma cells in the head and neck [50], and hepatocytes
[37] in vitro. Activation of EGF receptor triggers transmission
of signals involved in mitogen-activated protein kinases
(MAPK), phosphatidylinositol 3P-kinase (PI3-k)/Akt, and
the signal transducers and activators of transcription-3 path-
way [35,49,51]. In hepatocytes, EGF signaling can up-regulate
Bcl-xL expression via the MAPK and PI3-k/Akt pathways
[37]. Thus, TGFK may control the expression of Bcl-xL pro-
tein through these pathways in this mouse model. HGF has
been reported to prevent Fas-mediated liver apoptosis [29],
and, the same as TGFK, HGF strongly induces expression
of Bcl-xL but not of Bcl-2, thereby protecting against hepa-
tocyte apoptosis in vivo. However, there is a di¡erence in
intracellular signaling pathways, with the PI3-k/Akt pathway
having been reported to mainly contribute to Bcl-xL expres-
sion in hepatocytes stimulated by HGF [52].
In addition, accumulating evidence has shown that the
mouse model of Fas-mediated liver injury may involve a
mechanism similar to that in the fulminant hepatic failure
caused by hepatitis virus infection [5,15,53]. Tomiya et al.
reported that serum TGFK levels are correlated with the out-
come of fulminant hepatic failure [54]. We have documented
that TGFK transgenic mice dramatically survived Fas-medi-
ated lethal hepatic failure. These ¢ndings seem to support the
ability of TGFK to protect against fulminant failure. Admin-
istration of TGFK may be bene¢cial as a new option for
treatment of fulminant liver failure. The clinical use of
TGFK, however, needs further investigation because of its
initiation and promotion of hepatocarcinogenesis.
In conclusion, the results of our study con¢rm that TGFK
e⁄ciently protects against Fas-mediated liver injury in vivo
and suggest that elevated expression of Bcl-xL protein in re-
sponse to TGFK may participate in suppressing liver apopto-
sis.
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